Before-surgery treatment for triple-negative or BRCA breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 16 to 70 and able to sign consent and attend all study visits
- Invasive breast cancer confirmed by biopsy, and HER2-negative (and ER-negative for the triple-negative group)
- Either: triple-negative (ER-negative and HER2-negative) breast cancer, OR a inherited BRCA (gBRCA) mutation with HER2-negative breast cancer
- Your tumor should be considered locally advanced (for example: larger tumor, spread to certain lymph nodes, inflammatory cancer, or skin/chest wall involvement)
- You must have starting biopsy tissue available for multiple special lab tests and be well enough for chemotherapy (doctor says chemotherapy is safe; bone marrow/liver/kidney labs acceptable; general functioning score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.